Healthpoint is a biopharmaceutical and biotechnology company founded in 1992 with a commitment to providing innovative and cost-effective solutions for dermal repair and regeneration. The company's flagship product is Collagenase SANTYL® Ointment (SANTYL), an enzymatic debrider for treating dermal ulcers and burns, as well as the OASIS® range of acellular skin substitutes and REGRANEX®, a growth factor for managing diabetic foot ulcers.
The company is heavily focused on research and development, particularly in the area of chronic wound treatment. Their lead pipeline product, HP802-247, is undergoing Phase 3 trials for the treatment of venous leg ulcers using a cell-based therapy. Notably, in August 2011, Healthpoint announced promising results from a Phase 2b clinical trial for HP802-247, meeting both primary and secondary endpoints.
With a strong foothold in the biopharma and biotechnology industries, Healthpoint is poised for potential commercial launch of HP802-247 as early as 2017. The company's dedication to developing advanced products for chronic wound care positions it as a promising player in the healthcare sector.
